Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

MYC inhibitor

DRUG CLASS:

MYC inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
KRAS G12A	Chronic Myeloid Leukemia	KRAS G12A	Chronic Myeloid Leukemia	GT19077 Sensitive: C3 – Early Trials GT19077 Sensitive : C3	GT19077 Sensitive: C3 – Early Trials GT19077 Sensitive : C3
MAF overexpression	Multiple Myeloma	MAF overexpression	Multiple Myeloma	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
MRC1 expression	Small Cell Lung Cancer	MRC1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3
MYC translocation	Acute Myelogenous Leukemia	MYC translocation	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Acute Myelogenous Leukemia	IGH translocation	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC translocation	Multiple Myeloma	MYC translocation	Multiple Myeloma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Multiple Myeloma	IGH translocation	Multiple Myeloma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC translocation	Lymphoma	MYC translocation	Lymphoma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Lymphoma	IGH translocation	Lymphoma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D